This article discusses innovative methods of treating psoriasis, such as 2nd generation Janus kinase (JAK) inhibitors (deucravacitinib), a hydrogel (BVn) based on self-assembling bilirubin nanoparticles and an inhibitor of the amino acid transporter ASCT2 (V9302), a microneedle patch based on hyaluronic acid and two-dimensional inorganic compounds (maxenes), used to introduce monoclonal antibodies (MAbs) directly into the psoriatic lesion, NLRP3 inflammasome inhibitors.
When analyzing modern studies devoted to the evaluation of promising methods for treating psoriasis, two main trends were noted: further research into drugs based on small molecules and the development of new MAbs for more effective and affordable treatment of psoriasis. In addition, current treatment strategies are aimed at relieving symptoms, improving quality of life, and preventing the progression of psoriasis. However, existing methods are limited by side effects, treatment resistance and high costs. These limitations highlight the urgency of searching for new innovative treatment methods.
The uniqueness of this work lies in the fact that it most fully presents the above methods of therapy, and when searching for modern works for analysis, Russian-language articles mainly described new genetically engineered biological drugs (GEBPs), such as interferons, interleukins and Mabs, were used.

Keywords: inflammasome, intradermal administration, Janus kinase inhibitors, nanoparticles, psoriasis